NCT04484012View on ClinicalTrials.gov

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 31, 2020

Primary Completion Date

September 2, 2025

Study Completion Date

September 2, 2025

Conditions
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
Interventions
DRUG

Acalabrutinib

Given PO

BIOLOGICAL

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

Given IV

Trial Locations (1)

91010

RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER